Expert Analysis

Prepping For The Future Of No Surprises Act Enforcement

This year is expected to be a transition point for the No Surprises Act framework from regulatory delay to operati... (more story)

High Court's 'Skinny Label' Case May Tackle Wider Questions

The U.S. Supreme Court's upcoming decision in Hikma v. Amarin will have important ramifications for broader debate... (more story)

FDA's Biosimilarity Guidance Holds Uncertain Implications

The U.S. Food and Drug Administration's new draft guidance aimed at simplifying the biosimilarity demonstration pr... (more story)

Deals & Corporate Governance More

Florida Man Pleads Guilty In $24M HIV Drugs Fraud Scheme

The owner of a marketing company in Florida has pled guilty to receiving kickbacks as part of a $24 million scheme to sign up Medicare and Medicaid beneficiaries for HIV prophylactic medications they did not need.

Healthcare REIT Picks Up $64M Senior Housing Portfolio

Real estate investment trust National Healthcare Properties Inc. has agreed to buy a $64 million collection of senior living communities to capitalize on the country's aging population and limited supply of ne... (more story)

Fed. Circ. Revives Challenge To Augmented Reality Surgical IP

The Federal Circuit on Tuesday partly revived a patent challenge brought by a medical technology company, overruling the Patent Trial and Appeal Board in saying that there was no motivation for one to combine ... (more story)

Taxation With Representation: Linklaters, Wilson Sonsini

In this week's Taxation With Representation, French electric utility Engie acquires UK Power Networks, Gilead Sciences Inc. buys clinical-stage biotechnology company Arcellx Inc., and The Brink's Co. acquires ... (more story)

Justices Told 'Skinny Label' Case Puts Generic Drugs At Risk

The U.S. government, one named sponsor of the Hatch-Waxman Act, a generic-drug industry group and more have warned the U.S. Supreme Court that a decision that allowed a patent case involving a so-called skinny... (more story)

9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case

The Ninth Circuit ruled against a lower court Wednesday in saying pharmaceutical giant Eli Lilly does not owe $278 million in royalties to an Arizona company for insulin-brands sales, saying an agreement betwe... (more story)

Digital Health & Technology More

FDA Targets Advertising For Knockoff Weight-Loss Meds

The U.S. Food and Drug Administration on Tuesday accused about 30 telehealth companies of illegally marketing compounded weight-loss and diabetes drugs, the agency's latest salvo in a crackdown on direct-to-co... (more story)

AI-Focused Generate Biomedicines Prices $400M IPO

The CEO of Generate Biomedicines, a biotechnology firm using artificial intelligence to develop therapies for immunology and oncology, on Friday rang the Nasdaq opening bell as the company expects to raise $40... (more story)

Health Co.'s 'Success Story' Misstep Holds HIPAA Lessons

Cadia Healthcare Facilities' fall settlement with the U.S. Department of Health and Human Services for improperly disclosing patients' protected health information in online success stories is an instructive e... (more story)

Kochava, FTC Near Deal To End Geolocation Privacy Suit

The Federal Trade Commission and Kochava Inc. told an Idaho federal judge Thursday that they have negotiated a final deal to resolve claims alleging the mobile app analytics provider illegally sold geolocation... (more story)

Centene Says Filed Rate Doctrine Dooms RICO, Fraud Claims

Centene Corp. urged an Illinois federal judge Tuesday to grant it partial judgment in a proposed class action by patients alleging the company violated racketeering laws and cheated them out of billions with b... (more story)

Abortion Pill Access, Tariff Questions And More In Court

Law360 Healthcare Authority looks at drugmakers' intervention in federal litigation concerning mail-order abortion medication, questions left open by the U.S. Supreme Court's decision striking down tariffs and... (more story)

Policy & Compliance More

BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit

Biopharmaceutical company BioAge Labs Inc. has escaped a suit accusing it of damaging investors by unexpectedly halting a clinical trial for a weight loss drug, with a California federal judge finding that the... (more story)

Inova Defeats Nurses' COVID Vax Bias Suits At 4th Circ.

The Fourth Circuit refused Tuesday to revive suits from nurse anesthetists who said they faced religious and disability discrimination when they were fired for refusing to get vaccinated against COVID-19, ruli... (more story)

Death From Stem Cell Treatment For ALS Draws $24M Verdict

A Washington state jury awarded $24 million to the family of a patient who died just two days after what his family members described as a "worthless" spinal cord procedure to treat his ALS at a Seattle stem cell clinic.

Ex-FDA Leaders Rebut Contraception Rollbacks At 3rd Circ.

Former FDA commissioners argued that Trump-era religious exemptions for birth control coverage jeopardize public health and distort medical science, in an animus brief filed Monday with the Third Circuit.

NC Doctor's Bid For New Trial Is Too Late, Judge Says

A North Carolina federal judge has refused to order a new trial for a doctor convicted of participating in an $11 million Medicare fraud scheme, finding that because the motion did not contain new evidence, th... (more story)

Elevance Sanction Adds To Medicare Advantage Troubles

Amid slowing enrollment rates and rising enforcement interest in private Medicare plans, insurer Elevance Health is being barred from signing up new patients to some prescription drug plans. It's not the only ... (more story)